Splichal James E, Stamm Jason A, Ornstein Deborah L
Department of Hematology and Oncology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, USA.
Semin Thromb Hemost. 2003 Jun;29(3):259-74. doi: 10.1055/s-2003-40964.
Statins are approved by the Food and Drug Administration (FDA) for the treatment of hypercholesterolemia and have shown remarkable activity in preventing cardiovascular morbidity and mortality. The versatility of statins is increasingly being appreciated, however, and lowering cholesterol is only one attribute among many shared by this class of drugs. Most statins appear to have antithrombotic activity that is unrelated to the ability to reduce cholesterol levels, and several have significant antitumor effects. This article reviews the laboratory and clinical evidence that statins have antithrombotic and anticancer activity, discusses the ways in which these two activities intersect, and proposes novel uses for statins for the treatment of conditions other than hypercholesterolemia.
他汀类药物已获美国食品药品监督管理局(FDA)批准用于治疗高胆固醇血症,并在预防心血管疾病的发病率和死亡率方面显示出显著活性。然而,他汀类药物的多功能性正越来越受到重视,降低胆固醇只是这类药物众多共同特性之一。大多数他汀类药物似乎具有与降低胆固醇水平的能力无关的抗血栓活性,并且有几种还具有显著的抗肿瘤作用。本文综述了他汀类药物具有抗血栓和抗癌活性的实验室及临床证据,讨论了这两种活性的交叉方式,并提出了他汀类药物在治疗高胆固醇血症以外病症方面的新用途。